I
L-12 is a heterodimeric cytokine that affects the growth and function of T and NK cells (1-4, for review see 5) . Studies with human and murine cells have shown IL-12 to promote the development of Thl cells, induce the secretion of IFN-3' from resting and activated T and NK cells, function as growth factor of T and NK cells, and enhance the cytolytic activity of NK cells and cytotoxic lymphocytes (6) (7) (8) (9) (10) . In addition, IL-12 synergizes with other cytokines such as kit ligand (KL), IL-3, and IL-11 in stimulating the proliferation and differentiation of early hematopoietic progenitors in vitro (11) (12) (13) (14) .
In contrast to the stimulation of hematopoietic cells seen in vitro, IL-12 administration reportedly induced neutropenia, lymphopenia, and anemia in mice (unpublished observations reviewed in reference 5). Here, we confirm these results and further document a marked reduction in bone marrow cellularity together with a lower content in hematopoietic precursor after IL-12 administration in mice. The apparent discrepancy between in vitro and in vivo effects of IL-12 on hematopoiesis may be explained by invoking secondarily produced antagonistic cytokines.
IL-12 was shown to strongly stimulate the transcription and secretion of IFN-3, by T cells and NK ceils both in vitro (1, 8, 15) and in vivo (16, 17) . IL-12 also induces TNF-c~ and IL-10 gene transcription in vivo (16) . In contrast, IL-3 and IL-4 gene expression are suppressed after IL-12 treatment (16) . Enriched human NK cells stimulated with IL-12 were recently reported to inhibit hematopoietic colony formation from bone marrow cells (18) . This was attributed to IL-12-induced expression of IFN-3, and TNF-ot by NK cells, suggesting that secondary cytokine production by lymphoid cells may play a role in the regulation of hematopoiesis (18) . IFN-3' has been reported to be a negative hematopoietic and lymphopoietic regulator, based both on in vitro data (19) (20) (21) (22) and on results obtained in vivo in mice and primates (for review see reference 23). The inhibitory effects of IL-12 treatment on in vivo hematopoiesis could therefore be a result of the IL-12-induced production of IFN-3,. In this study, IFN-3, receptor-deficient mice (24) were used to address this question and to differentiate between the respective effects of IL-12 and IFN-3, on hematopoiesis in vivo.
Materials and Methods
Reagents. Colony Assays from Spleen and Bone Marrow Cells. Cell suspensions from bone marrow and spleen prepared in isotonic balanced salt solution were counted in cytology chambers using Turk's coloration. Methylcellulose cultures were prepared in IMDM containing 4% FCS, BSA fraction V, transferrin, and lipids according to Iscove et al. (27) in the presence of optimized concentrations of erythropoietin (Epo; 0.08 U/ml) with either IL-3 (30 ng/ml) and IL-1 (10 ng/ml), or II.-11 (50/zl COS supernatant/ml) and KL (25/z] COS supernatant/ml), as indicated. Cells from treated mice were pooled for each group, and several concentrations of bone marrow (3-20 x 104 cells/ml) and spleen cells (1-3 x 105 cells/ml) were titrated in triplicate for each pool to ensure sufficient number of colonies per culture. Large (>1 mm) multilineage colonies comprising erythroid, megakaryocytic, and other myeloid cells, erythroid colonies (either pure or containing megakaryocytes) and GM colonies were counted on day 9. The colonies were identified by their morphology and were periodically picked, spread, and stained (Wright-Giemsa) for confirmation. Results from three to six culture plates are combined for each determination.
Statistics. All results are pooled from two independent experiments and are expressed as mean + SD with n = 4-8 animals per group. They were compared using the student's t test, and p <0.05 was considered statistically significant.
Results and Discussion
Since in vivo IL-12 administration was reported to induce neutropenia, lymphopenia, and anemia (5), we investigated the effect of IL-12 on hematopoiesis in normal mice. Mice were treated with 1 #g/mouse per d IL-12, a dose shown to give maximal effect on NK cell cytotoxic function (17), daily for 7 d and killed on day 8. Bone marrow cellularity was reduced from 12.5 _+ 2.5 million cells per femur in the placebo-treated mice to 4.8 _+ 1.1 million cells per femur in mice treated with IL-12 (n = 6). The frequency of bone marrow colony-forming hematopoietic progenitors (CFC) was also reduced by two-to fourfold after IL-12 treatment (not shown). The number of bone marrow cells per femur were already decreased by half, and the CFCs were reduced after 4 d of IL-12 treatment (see below; Figs. I and 2). Thus, in line with the depressed blood counts reported after IL-12 administration, we show that a short course of II.-12 was strongly myelodepressive in wild-type mice.
There was an apparent discrepancy between the in vivo myelotoxicity of IL-12 and its positive effects on hematopoietic progenitors in vitro. Indeed, in vitro, IL-12 was shown to synergize with other cytokines such as KL, IL-3, and IL-11 to stimulate the proliferation and differentiation of early hematopoietic progenitors (11, 13, 14, 18) . These results were obtained with highly purified progenitors or even single cells, thus under conditions where the IL-12 effects observed were likely to be direct. IL-12 myelotoxicity in vivo could, however, be explained by some indirect mechanisms. Since IL-12 has a profound stimulatory effect on IFN-3' production by T cells and NK cells both in vitro (1, 8) and in vivo (16, 17) , we hypothesized that the inhibition of hematopoiesis We then examined the effect of II,-12 treatment in mice rendered unresponsive to IFN-y after inactivation of the IFN-'y receptor gene (24) . First, we established that untreated IFN-'y receptor-deficient (IFNyR -/-) mice maintained under SPF conditions have essentially normal hematopoietic parameters in terms of bone marrow cellularity and CFC content, as well as spleen weight, cellularity, and number of CFC (not shown). Wild-type and IFN'yR -/-mice were then treated for 4 d with 1 #g/mouse per d of IL-12 and killed on day 5. In wild-type mice, this treatment resulted in mild anemia with reticulocytosis, some lymphopenia, and a 3.3-fold decrease in neutrophils (Table 1 ). In I F N y R -/-mice, the only significant change of peripheral blood counts observed after IL-12 treatment was a 1.8-fold increase of neutrophil counts (Table 1) , although the levels of circulating IFN-3' were as high as 1,036 -+ 322 ng/ml after IIA2 treatment (compared with 0.9 + 1.5 ng/ml in placebo-treated controls, n = 8). There was a significant twofold reduction in bone marrow cellularity in IL-12-treated wild-type mice compared with the placebo-treated controls (Fig. 1) . In contrast, bone marrow cellularity was not significantly affected after IL12 treatment in I F N y R -/-mice (Fig. 1) . Thus, the reduction of peripheral blood cells and the overall decrease in bone marrow cellularity seen after IL-12 administration seemed to be mediated by IFN-y.
Cytological analysis of bone marrow preparations confirmed that the nonmitotic mature bone marrow cell population was markedly depleted in wild-type but not in IFN'yR -/-mice treated with IL-12 for 4 d. In wild-type mice, IL-12 treatment resulted in a significant 11.2-fold reduction of erythroid elements and 4.7-fold depletion of lymphoid cells, plus a slight nonsignificant reduction of neutrophilic and eosinophilic precursors, respectively ( Table 2 ). Identifiable monocytic precursors were significantly increased by 2.2-fold, and both myeloblast and erythroblast numbers were normal ( Table 2) . In IFN'yR -/-mice, however, IL-12 treatment caused only a slight, nonstatistically significant decrease in erythroid and lymphoid elements (Table 2 ). Neutrophilic precursors were 2.9-fold decreased, while monocytic precursors were 1.5-fold increased (Table 2) . In contrast to wild-type mice, there was a significant increase in eosinophilic precursors (1.6-fold) and blasts (2.2-fold, predominantly myeloblasts) after IL-12 treatment of I F N y R -/-mice. Thus, although IL-12 induced monocytopoiesis in both wild-type and IFN3,R -/-mice, the suppression of most other cell lineages was absent or less severe in I F N y R -/-mice, and blasts were increased only in mice that were unresponsive to IFN-'y.
We next studied the effect of a 4-d I1,-12 treatment on hematopoietic progenitors. In wild-type mice, the absolute numbers of erythroid-and GM-CFC per femur were threeto fivefold decreased after IL-12 treatment, although this difference, based on two experiments with pooled bone marrow cells within groups of mice, did not reach statistical significance. In IFNTR -/-mice treated with Ib12, there was no decrease but rather a trend to increase all CFCs (Fig.  2) . Even though the total cellularity per femur was twofold decreased in the Ib12-treated wild-type mice, the frequency of CFC was still twofold lower in these mice compared to placebo-treated controls. In contrast, the IL-12 treatment of IFN3~R-/-mice resulted in up to a twofold increase of CFC frequency without decreasing the total marrow cellularity. Therefore, a short IL-12 treatment, which depresses bone marrow hematopoietic progenitors in wild-type mice, tends to increase these progenitors in mice rendered unresponsive to IFN-% Ib12 induced splenomegaly in wild-type mice, as spleen weight was 5. Fig. 3) . This was due, at least in part, to monocytic infiltrates and a high NK cell content (histology not shown). FACS | analysis from splenocyte suspensions also showed a doubling of CDllb + cells and a threefold increase of NKI.1 + cells (Fig. 4) . Splenic hematopoiesis was slightly increased after 4 d of IL-12 treatment as seen histologically (not shown) and by some increase in the absolute number of splenic CFC, which did not reach stastistical significance (Fig. 5) . Thus, in wild-type mice, IL-12 induces splenomegaly, which is caused by both macrophage and NK cell infiltration in addition to some extramedullary hematopoiesis.
IL - significance (Fig. 3) . FACS | analysis from splenocyte suspension showed a doubling of CD11b § cells but no increase in NKI.1 + cells in IL-12-treated IFN3,R -/-mice (Fig. 4) . The total number of CFC per spleen was increased in these mice after 4 d of IL-12 treatment, and this was particularly significant for erythroid CFC (Fig. 5) . The frequency of CFC on a per cell basis was also 3.7-fold increased in the IL-12 treated IFN3~R -/-mice, compared with 1.7-fold only in the wild-type mice. Therefore, the increases in splenic weight, cellularity, and NK cell infiltration after IL-12 treatment were less pronounced in IFN3,R -/-mice than in wild-type mice. In contrast, the frequency and the absolute number of splenic CFC were higher after IL-12 treatment in IFN3,R -/-than in wild-type mice.
In conclusion, the effects attributable to IFN-3~ after IL-12 treatment include the reduction in bone marrow total cellularity, in identifiable myeloid, erythroid, and lymphoid elements and in hematopoietic colony-forming progenitors, and the dramatic increase of splenic cellularity, mainly due to NK cell and macrophage infiltration. In an environment nonresponsive to IFN-% ILo12 does not reduce mature bone marrow cells, moderately affects identifiable myeloid, erythroid and lymphoid elements, and tends to increase blasts and colony-forming progenitors in the bone marrow. Splenic hematopoiesis is also increased in IL-12-treated IFNq~R -/- mice, although there is a more moderate increase in splenic total cellularity with a markedly lower NK cell content. It seems that, in the absence of IFN-y signaling, an important costimulatory signal is missing to allow full stimulation of NK cell proliferation by IL-12.
The results obtained in the absence of the IFN-y negative regulation in mice rendered deficient for IFN-3~ receptor are therefore compatible with the direct stimulation of early hematopoietic progenitors by ILo12 seen in vitro (12) (13) (14) . However, the enhancement of bone marrow progenitors stimulated by IL-12 appears to be balanced in vivo by the production of IFN-% which acts in a dominant myelosuppressive fashion. Thus, although IFN-3~ does not seem to be essential for steadystate hematopoiesis, as seen in mice deficient for IFN-y production (28) or signaling (24), we demonstrate here that IFN-y is clearly a potent negative regulator of hematopoiesis when induced in response to IL-12. Since high levels of IL-12 are produced systemically during endotoxemia, this negative regulatory function of IFN-y is likely to be of pathophysiological significance for the acute hematological alterations seen after bacterial infections.
